Lupus & antiphospholipid syndrome
Treat to target and shared decision-making in systemic lupus erythematosus from the patients' perspective: results from an international patient survey
Authors' conclusion
T2T was perceived as beneficial with improvement of QoL as the most important treatment goal and the possibility of additional doctors' visits and initiation of new immunosuppressive agents as potential drawbacks.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) from Dutch, Austrian, German and Bulgarian patient organisations
- Participants
- 863 patients
- Outcome
- Patients' attitude towards T2T and their involvement in treatment decisions
Methodological detailsonline survey, 13-question survey, international
- Online survey
- 13-question survey
- International
Main finding
As reported in the abstract
Attitude towards T2T, shared decision-making and satisfaction
- Reported being in remission
- 48.4%
- Uncertain about remission status
- 13%
- Somewhat fully involved in treatment decisions
- 62.1%
- Felt uninvolved in treatment decisions
- 20.7%
- Somewhat fully satisfied with health status
- 56.2%
- Unsatisfied with health status
- 29.3%
- Satisfied with treatment
- 65.5%
- Not satisfied with treatment
- 14.8%
- Leading treatment goal: Quality of life (QoL) normalisation
- 37.4%
- Leading treatment goal: organ damage prevention
- 24.6%
- Leading treatment goal: absence of disease activity
- 22.6%
Observational data: associations, not effects.
Original publication
Treat to target and shared decision-making in systemic lupus erythematosus from the patients' perspective: results from an international patient survey. Clin Exp Rheumatol. Published 12 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →